Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV Melanoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Feb 2018
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 07 Feb 2018 Planned End Date changed from 1 Feb 2019 to 1 Feb 2021.
- 07 Feb 2018 Planned primary completion date changed from 1 Feb 2019 to 1 Feb 2020.
- 14 Jul 2017 Status changed from recruiting to active, no longer recruiting.